← Eichor
Study identifier: NCT07204457 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

Condition: Meningococcal Infections  ·  Sponsor: EyeGene Inc.

PhasePhase 2/Phase 3
Planned participants1123
Who can joinAll sexes, 19 Years to 55 Years
Healthy volunteersYes

About this study

Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine

This description comes directly from the study's public registry record.

Talk to the study team

Jooyoung Park  ·  +82-2-322-1687  ·  jypark@eyegene.co.kr

Kyung-Hee Lee  ·  +82-2-322-1687  ·  seagreen@eyegene.co.kr

Always discuss trial participation with your own doctor first.

Locations (1)

The Catholic University of Eunpyeong St.Mary's HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07204457